Aadi Bioscience Analyst Ratings
Aadi Bioscience Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | 689.47% | HC Wainwright & Co. | $45 → $36 | Maintains | Buy |
| 08/10/2023 | 886.84% | HC Wainwright & Co. | → $45 | Reiterates | Buy → Buy |
| 06/08/2023 | 886.84% | HC Wainwright & Co. | → $45 | Reiterates | Buy → Buy |
| 05/17/2023 | 886.84% | HC Wainwright & Co. | → $45 | Reiterates | Buy → Buy |
| 03/29/2023 | 886.84% | HC Wainwright & Co. | $48 → $45 | Maintains | Buy |
| 04/11/2022 | 952.63% | HC Wainwright & Co. | $49 → $48 | Maintains | Buy |
| 01/11/2022 | 886.84% | Jefferies | → $45 | Initiates Coverage On | → Buy |
| 11/24/2021 | 974.56% | HC Wainwright & Co. | $47 → $49 | Maintains | Buy |
| 10/01/2021 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 09/14/2021 | 1018.42% | Ladenburg Thalmann | → $51 | Initiates Coverage On | → Buy |
| 09/08/2021 | 886.84% | Piper Sandler | → $45 | Initiates Coverage On | → Overweight |
| 08/30/2021 | 930.7% | HC Wainwright & Co. | $22 → $47 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/13/2023 | 689.47% | HC Wainwright & Co. | 45 美元 → 36 美元 | 維護 | 買 |
| 08/10/2023 | 886.84% | HC Wainwright & Co. | → 45 美元 | 重申 | 購買 → 購買 |
| 06/08/2023 | 886.84% | HC Wainwright & Co. | → 45 美元 | 重申 | 購買 → 購買 |
| 05/17/2023 | 886.84% | HC Wainwright & Co. | → 45 美元 | 重申 | 購買 → 購買 |
| 03/29/2023 | 886.84% | HC Wainwright & Co. | 48 美元 → 45 美元 | 維護 | 買 |
| 2022 年 11 月 4 日 | 952.63% | HC Wainwright & Co. | 49 美元 → 48 美元 | 維護 | 買 |
| 01/11/2022 | 886.84% | 傑富瑞集團 | → 45 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 11/24/2021 | 974.56% | HC Wainwright & Co. | 47 美元 → 49 美元 | 維護 | 買 |
| 2021 年 1 月 10 日 | — | Cowen & Co. | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 2021 年 9 月 14 日 | 1018.42% | 拉登堡塔爾曼 | → 51 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 09/08/2021 | 886.84% | 派珀·桑德勒 | → 45 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2021 年 8 月 30 日 | 930.7% | HC Wainwright & Co. | 22 美元 → 47 美元 | 維護 | 買 |
What is the target price for Aadi Bioscience (AADI)?
Aadi Bioscience（AADI）的目標價格是多少？
The latest price target for Aadi Bioscience (NASDAQ: AADI) was reported by HC Wainwright & Co. on November 13, 2023. The analyst firm set a price target for $36.00 expecting AADI to rise to within 12 months (a possible 689.47% upside). 5 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年11月13日公佈了Aadi Bioscience（納斯達克股票代碼：AADI）的最新目標股價。該分析公司將目標股價定爲36.00美元，預計AADI將在12個月內升至12個月內（可能上漲689.47％）。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for Aadi Bioscience (AADI)?
分析師對Aadi Bioscience（AADI）的最新評級是多少？
The latest analyst rating for Aadi Bioscience (NASDAQ: AADI) was provided by HC Wainwright & Co., and Aadi Bioscience maintained their buy rating.
HC Wainwright & Co. 對Aadi Bioscience（納斯達克股票代碼：AADI）的最新分析師評級由HC Wainwright & Co. 提供，阿迪生物科學維持買入評級。
When is the next analyst rating going to be posted or updated for Aadi Bioscience (AADI)?
Aadi Bioscience（AADI）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aadi Bioscience, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aadi Bioscience was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Aadi Bioscience的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Aadi Bioscience的最新評級是在2023年11月13日公佈的，因此您應該預計下一個評級將在2024年11月13日左右公佈。
Is the Analyst Rating Aadi Bioscience (AADI) correct?
分析師對Aadi Bioscience (AADI) 的評級是否正確？
While ratings are subjective and will change, the latest Aadi Bioscience (AADI) rating was a maintained with a price target of $45.00 to $36.00. The current price Aadi Bioscience (AADI) is trading at is $4.56, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Aadi Bioscience（AADI）評級保持不變，目標股價爲45.00美元至36.00美元。Aadi Bioscience（AADI）目前的交易價格爲4.56美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。